Global Pompe Disease Treatment Market, By Type (Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Others), Diagnosis (Blood Test, Genetic Test, Prenatal Test, Others), Treatment (Enzyme Replacement Therapy, Supportive Therapies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Pompe Disease Treatment Market Analysis and Size
The global pompe disease treatment market is projected to witness significant growth during the forecast period. In U.S., projected occurrence are approximately 1 in 40,000 births. Males and females are equally affected by the diseases. Medical advancements that involves ongoing drug discovery, and government and non-government organizational initiatives are what that boosts the market growth.
Data Bridge Market Research analyses a growth rate in the global pompe disease treatment market in the forecast period 2022-2029. The expected CAGR of global pompe disease treatment market tend to be around 4% in the mentioned forecast period. The market was valued at USD 1.4 billion in 2021, and it would grow upto USD 1.92 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Pompe disease is an autosomal recessive inherited disorder caused by pathogenic variations in the acid alpha-glucosidase (GAA) gene. It is characterized by the abnormal build up of sugar (glycogen) inside the cells, this sugar builds up the working of different organs and tissues, specifically heart, skeletal muscles and respiratory tract. Patients suffering from the classic infantile form type of pompe disease are most affect patients. In infants, symptoms are usually seen in three months with rapidly muscle weakness, respiratory insufficiency, hypertrophic cardiomyopathy.
Pompe Disease Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Others), Diagnosis (Blood Test, Genetic Test, Prenatal Test, Others), Treatment (Enzyme Replacement Therapy, Supportive Therapies, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Amicus Therapeutics, Inc (U.S.), Audentes Therapeutics (U.S.), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Akorn Incorporated (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Danaher. (U.S.), B.D. (U.S.), Chembio Diagnostics (U.S.), EKF Diagnostics (U.K.), Trinity Biotech plc (Ireland), Instrumentation Laboratory (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), Sekisui Diagnostics (U.S.), Thermo Fisher Scientific (U.S.), bioMérieux S.A. (France)
|
|
Market Opportunities
|
|
Global Pompe Disease Treatment Market Dynamics
Drivers
- Increased Incidence of Pompe Disease
Pompe disease affects 1 in 40,000 individuals in the U.S. It has been observed that the total carrier frequency (C.F.) and predicted genetic prevalence (pGP) were about 1.3 % and 1:23,232, respectively. Its frequency is growing and its treatment is of great importance to the healthcare sector.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is projected to increase the global market as most products are available in capsule and tablet form and it is a very convenient route of administration.
Opportunities
- Increased Research and Clinical Activities
Launching novel drugs globally will boost the demand for treatment of pompe disease and boost the market growth. In addition to this, increasing R&D expenditure will more involvement on novel therapeutics of pompe diseases as this is a very vital and fatal disease. For Instance, Genethon developed a gene therapy clinical trial for late-onset Pompe disease in February 2021 using technologies developed at Genethon. This creates more opportunity in the market.
- Rising Demand of Advanced Treatments
The growing incidence of Pompe disease provides opportunities for treatment providers who have developed several new products and services that are focused on improving patient outcomes through numerous medications, medical devices, surgical procedures, rehabilitation therapies, pharmaceuticals, and other interventions. Thus, these treatments create more opportunities for the market growth.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of the treatment methods for this disease could curb the growth of the global pompe disease treatment market over a forecast period.
- High Cost
The huge expenditure of the treatment methods hamper the market growth. The treatment for this diseased condition is expensive, and only about one-third of patients who receive it survive beyond five years. There is a high degree of unmet medical need for pompe disease treatment.
This global pompe disease treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pompe disease treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Pompe Disease Treatment Market
COVID-19 has left a global public health crisis that has impacted practically every business. The transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
The global pompe disease treatment market witnessed a huge negative transition during the COVID-19 pandemic as there was a decline in patient hospitalizations. Only emergency and primary care services are available during COVID-19. Patients suffering from pompe disease are at very high risk. Thus, COVID-19 significantly impacted the pompe diseases market.
Global Pompe Disease Treatment Market Scope
The global pompe disease treatment market is segmented on the basis of type, diagnosis, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Classic Infantile Form
- Non-Classic Infantile Form
- Late-Onset Form
- Others
Diagnosis
- Blood Test
- Genetic Test
- Prenatal Test
- Others
Treatment
- Enzyme Replacement Therapy
- Supportive Therapies
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Pompe Disease Treatment Market Regional Analysis/Insights
The global pompe disease treatment market is analysed and market size insights and trends are provided by type, diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global pompe disease treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the pompe disease treatment market due to the presence of major key players, high disposable income and well-developed healthcare sector in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Pompe Disease Treatment Market Share Analysis
The global pompe disease treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global pompe disease treatment market .
Key players operating in the global pompe disease treatment market include:
- Amicus Therapeutics, Inc (U.S.)
- Audentes Therapeutics (U.S.)
- Novartis AG (Switzerland)
- Fresenius Kabi AG (Germany)
- Akorn Incorporated (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Mylan N.V (U.S.)
- Johnsons & Johnsons Services Inc (U.S.)
- F. Hoffman-La Roche Ltd. (Switzerland)
- Danaher. (U.S.)
- B.D. (U.S.)
- Chembio Diagnostics (U.S.)
- Sekisui Diagnostics (US)
- Thermo Fisher Scientific (U.S.)
- bioMérieux S.A. (France)
SKU-